1. Introduction {#sec1}
===============

Macular corneal dystrophy (MCD) is an autosomal recessive corneal stromal dystrophy characterized by bilateral diffuse stromal haze and scattered focal stromal opacities that predominantly involve the anterior stroma in the center of the cornea and the posterior stroma in the peripheral cornea.[@bib1] Mutations in the carbohydrate sulfotransferase 6 gene (*CHST6*) are causative of MCD, with both coding region and promoter mutations identified.[@bib2] CHST6 protein in human cornea is responsible for the enzymatic sulfation of keratan sulfate (KS),[@bib3] a key process in collagen matrix assembly and homeostatis.[@bib4] While sulfated KS is not detectable in the cornea of individuals with MCD, and serum levels are either absent (type I) or decreased (type II), unsulfated KS is, depositing both in keratocytes and the stroma, as well as in endothelial cells and Descemet membrane.[@bib1]^,^[@bib5] Here we report a case of MCD type II, confirmed by genetic analysis and serum KS measurement, with isolated peripheral Descemet membrane deposits without the characteristic diffuse stromal haze and anterior stromal opacities.

2. Materials and methods {#sec2}
========================

A complete ophthalmic examination was performed, and after informed consent was obtained (UCLA IRB \# 11-000020), saliva and serum samples were collected. Sanger sequencing of the *CHST6* gene was performed on genomic DNA extracted from the saliva sample using previously described primers and reaction conditions.[@bib2] Sequences were compared to the wild type *CHST6* transcript (NM_021615.4) and minor allele frequencies (MAF) of identified variants were obtained from the Exome Aggregation Consortium (ExAC) and 1000 Genomes Project databases. Allele-specific cloning followed by sequencing was performed to determine the phase (*cis* or *trans*) of identified heterozygous mutations. In brief, a DNA fragment containing both mutation sites and a single SacII digestion site was amplified (primers: 5′-GATCCGTGGGTGATGTTATGGA-3′ and 5′-CAGGTGCTGAGGAACCTCTAA-3′), ligated into pCR™4-TOPO® TA vector using TOPO® TA Cloning Kit (Thermo Fisher Scientific), and expanded in competent *E. coli HST08 *cells (Takara Bio USA) with carbenicillin selection. Plasmids containing the desired DNA fragment were purified, digested by SacII restriction enzyme, size-selected on electrophoresis and sequenced. *In silico* prediction of non-canonical 5′ untranslated region (5' UTR) translation initiation sites and determination of the predicted initiation confidence was performed with PreTIS software.[@bib6] Serum glycosaminoglycans (GAG), including dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS), were measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS) as described previously and compared with four age-matched controls.[@bib7]

3. Case report {#sec3}
==============

A 68-year-old Asian male with an unremarkable past medical history noted a progressive decrease in visual acuity of both eyes. He was diagnosed with an unknown corneal dystrophy and referred to one of the authors (AJA) for molecular genetic analysis. The patient denied a family history of corneal disorders or corneal transplantation. Corrected visual acuities measured 20/40 OD and 20/50 OS. Slit lamp and OCT examination revealed bilateral clear corneas with the exception of peripheral, round, gray-white discrete deposits at the level of Descemet membrane ([Fig. 1](#fig1){ref-type="fig"}). Other than 2 + nuclear sclerotic cataracts, the remainder of the ocular exam was unremarkable in both eyes. Serial central corneal pachymetry measurements ranged from 479 to 517 μm OD and 519 to 531 μm OS. Corneal topography was unremarkable, with average keratometry values of 42.1 D OD and 43.1 D OS. Similarly, endothelial cell density was within normal limits in each eye, measuring 2381 cells/mm^2^ OD and 2083 cells/mm^2^ OS. Based on the morphology of the corneal opacities, the decreased central corneal thickness and the absence of a family history, a presumptive diagnosis of MCD was made, prompting screening of *CHST6* for confirmation of the diagnosis.Fig. 1**Macular corneal dystrophy associated with peripheral Descemet membrane opacities.** A. Slit-lamp photographs of the right and left eyes of an individual with macular corneal dystrophy demonstrating bilateral peripheral posterior stromal opacities. B. Anterior segment OCT images of the right and left eyes demonstrating that the deposits were located at the level of Descemet membrane (arrowheads).Fig. 1

Two heterozygous variants in *CHST6* were identified, c.-26C \> A in the 5′ UTR and c.803A \> G p.(Tyr268Cys) ([Fig. 2](#fig2){ref-type="fig"}A), which were confirmed to be located on separate alleles by allele-specific cloning (in *trans,* [Fig. 2](#fig2){ref-type="fig"}B, D). The c.-26C \> A variant is novel and is located in *CHST6* non-coding exon 2 in a "Kazak consensus", a favorable sequence context for translation preinitiation complex assembly.[@bib8] This variant is predicted to create a novel transcription initiation site followed by a 60-bp upstream open reading frame (uORF′) in mutant *CHST6* mRNA ([Fig.2](#fig2){ref-type="fig"}E). *In silico* analysis predicted that the uORF′ will be used as alternative translation ORF with 73.8% confidence ([Fig. 2](#fig2){ref-type="fig"}C). The alternative usage of the new uORF' is expected to attenuate translation of the wild-type *CHST6* main ORF (mORF), with the predicted mutant protein being only 19 amino acid in length, distinct from the CHST6 wild-type protein ([Fig. 2](#fig2){ref-type="fig"}E and F). The c.803A \> G variant, located in *CHST6* coding exon 3 and predicted to result in a missense amino acid substitution (p.(Tyr268Cys)), is a rare variant (rs72547539; MAF 0.0002 (1000 Genome) and 0.000009 (ExAC)), that has been previously reported in four probands with MCD.[@bib9]^,^[@bib10] Measurement of serum sulfated KS and other GAG revealed decreased serum levels of all GAG compared to four aged-matched controls ([Table 1](#tbl1){ref-type="table"}). The serum total sulfated KS level (134.6 ng/ml) was only 30% of that in age-matched controls.Fig. 2***CHST6* mutations and associated mRNA and protein changes in individual with macular corneal dystrophy.** A. Chromatograms showing identified heterozygous mutations c.-26C \> A and c.803A \> G (red rectangles). B. Allele specific cloning results showing c.-26C \> A and c.803A \> G (red rectangles) on separate alleles. Mutation c.-26C \> A is located in a Kozak sequence (green rectangle) (nt = nucleotide). C. *In silico* analysis showing the c.-26C \> A mutation creates a new translation initiation site at position 155 nt with moderate to high predicted initiation confidence. (The initiation site at 117 nt was seen in both wild type and mutant alleles.) (WT = wild-type) D. Schematic illustration of identified mutations *in trans*. (gDNA = genomic DNA) E. Schematic illustration of identified mutations in *CHST6* mRNA. Mutation c.-26C \> A induced r.155C \> A change in *CHST6* mRNA creating a new uORF (uORF′) (uORF = upstream open reading frame, green solid rectangle; mORF = main open reading frame, yellow solid rectangle). F. Schematic illustration of predicted protein changes in proband CHST6 protein. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article).Fig. 2Table 1Serum glycosaminoglycan levels in individual with macular corneal dystrophy.Table 1Age (yrs)KS (ng/ml)DS (ng/ml)HS (ng/ml)Di-S KS [a](#tbl1fna){ref-type="table-fn"}Mono-S KS [b](#tbl1fnb){ref-type="table-fn"}Total sulfated KSΔDi-4S [c](#tbl1fnc){ref-type="table-fn"}ΔDiHS-NS [d](#tbl1fnd){ref-type="table-fn"}ΔDiHS-oS [e](#tbl1fne){ref-type="table-fn"}ControlA62150.9301.4452.317.96.036.8B57122.0325.3447.413.17.056.8C59158.7317.2475.915.08.257.9D60120.4282.2402.521.212.974.3Mean (SD)60 (2)138.0 (19.7)306.5 (19.0)444.5 (30.7)16.8 (3.5)8.5 (3.1)56.5 (15.4)Proband6858.576.1134.64.63.632.0[^1][^2][^3][^4][^5][^6]

4. Discussion {#sec4}
=============

We report a unique phenotype of MCD associated with isolated peripheral Descemet membrane opacities without the characteristic diffusely distributed cornea stromal maculae. In contrast to the belief that abnormalities of corneal endothelium and Descemet membrane in MCD are secondary to diffused and/or phagocytosed pathological materials from the stroma, this report provides support for the alternative hypothesis that MCD primarily involves the corneal endothelium in addition to stromal keratocytes.[@bib11] Snip et al. reported that in MCD, the fibrillogranular material in vacuoles in the corneal endothelium contained the same acid mucopolysaccharide as in the vacuoles in the stromal keratocytes, and concluded that given the physical barrier of Descemet membrane, it was unlikely that the material in the endothelial vacuoles was phagocytosed.[@bib11] Additionally, the authors reasoned that the fact the posterior non-banded zone of Descemet membrane, which is produced by the corneal endothelium, is abnormal in MCD is evidence of corneal endothelial dysfunction in MCD.[@bib11] Quantock et al. also reported an unremarkable anterior banded zone but abnormal posterior non-banded zone of Descemet membrane with guttae and corneal endothelium demonstrating intracytoplasmic inclusions in a cornea of an individual with macular corneal dystrophy type II.[@bib12]

*In* *silico* analysis of the identified non-coding *CHST6* mutation that we report predicted the creation of a new uORF′ reducing *CHST6* mRNA translation efficiency from the mORF. Mutation-introduced uORF have been associated with many human diseases with experimental data showing reduced translational efficiency, and a 30--80% decrease in protein levels.[@bib13] Evidence for the potential pathogenicity of the identified c.-26C \> A mutation is provided by the fact that it demonstrates two of the four uORF properties associated with greater inhibition of downstream mORF translation: creation in a strong Kozak consensus context and location at a significant distance (\>99 nt) from the mRNA 5' cap.[@bib13] Therefore, the result is predicted to be an attenuation of production of the wild-type CHST6 protein and the production of a mutant, truncated CHST6 protein. In combination with the missense mutation previously associated with MCD on the opposite allele, these two mutations likely result in a decrease in both corneal and serum sulfated KS and the development of the peripheral Descemet membrane opacities that in this case, are the sole clinical manifestation of MCD.

5. Conclusions {#sec5}
==============

Macular corneal dystrophy may present with isolated involvement of Descemet membrane, providing evidence that corneal endothelial involvement is a primary manifestation of this autosomal recessive corneal dystrophy. Screening of the *CHST6* gene and measurement of serum keratan sulfate are useful means to confirm or exclude the diagnosis of MCD in cases with an atypical phenotype, which is necessary prior to reporting an expansion of the clinical phenotype associated with MCD.
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[^1]: KS: keratin sulfate; DS: dermatan sulfate; HS: heparan sulfate.

[^2]: Di-S KS: di-sulfated KS, Gal(6S)β1 → 4GlcNAc(6S).

[^3]: Mono-S KS: mono-sulfated KS, Galβ1 → 4GlcNAc(6S).

[^4]: ΔDi-4S \[ΔHexUAα1--4GlcNAc(4-O-sulfate)\]: 2-acetamido-2-deoxy-4-O-(4-deoxy-a-L-threohex-4-enopyranosyluronic acid)-4-O-sulfo-D-glucose.

[^5]: ΔDiHS-NS \[ΔHexUAα1-4GlcN(2-N-sulfate)\]: 2-deoxy-2-sulfamino-4-O-(4-deoxy-a-L-threo-hex-4-enopyranosyluronic acid)-D-glucose.

[^6]: ΔDiHS-oS (ΔHexUAα1--4GlcNAc): 2-acetamido-2-deoxy-4-O-(4-deoxy-a-L-threo-hex-4-nopyranosyluronic acid) -D-glucose.
